102 related articles for article (PubMed ID: 9376383)
1. [Modulation of P-fimbriation by ciprofloxacin in uropathogenic Escherichia coli].
Abalia I; Rodríguez E; Umaran A; Lacalle J; Sarasua A; Huarte M; Ramón Bilbao J
Enferm Infecc Microbiol Clin; 1997 May; 15(5):255-9. PubMed ID: 9376383
[TBL] [Abstract][Full Text] [Related]
2. Sub-MIC ciprofloxacin effect on fimbrial production by uropathogenic Escherichia coli strains.
Lo Bue AM; Geremia E; Castagna C; Chisari G; Nicoletti G
J Chemother; 1999 Oct; 11(5):357-62. PubMed ID: 10632381
[TBL] [Abstract][Full Text] [Related]
3. Effects of subinhibitory concentrations of amikacin and ciprofloxacin on the hydrophobicity and adherence to epithelial cells of uropathogenic Escherichia coli strains.
Wojnicz D; Jankowski S
Int J Antimicrob Agents; 2007 Jun; 29(6):700-4. PubMed ID: 17382520
[TBL] [Abstract][Full Text] [Related]
4. Effects of minimum inhibitory concentrations of three antimicrobials on the growth cell and fimbriation of uropathogenic Escherichia coli.
Padilla C; Vásquez M; Faúndez O
Rev Latinoam Microbiol; 1991; 33(2-3):105-8. PubMed ID: 1688318
[TBL] [Abstract][Full Text] [Related]
5. [Relation between P-fimbriae and resistance to amoxicillin, carbenicillin and tetracycline in uropathogenic strains of Escherichia coli].
Vranes J; Schönwald S; Zagar Z
Lijec Vjesn; 1994; 116(7-8):178-81. PubMed ID: 7853994
[TBL] [Abstract][Full Text] [Related]
6. Are quinolone-resistant uropathogenic Escherichia coli less virulent?
Vila J; Simon K; Ruiz J; Horcajada JP; Velasco M; Barranco M; Moreno A; Mensa J
J Infect Dis; 2002 Oct; 186(7):1039-42. PubMed ID: 12232848
[TBL] [Abstract][Full Text] [Related]
7. Risk factors for ciprofloxacin resistance among Escherichia coli strains isolated from community-acquired urinary tract infections in Turkey.
Arslan H; Azap OK; Ergönül O; Timurkaynak F;
J Antimicrob Chemother; 2005 Nov; 56(5):914-8. PubMed ID: 16174685
[TBL] [Abstract][Full Text] [Related]
8. Phylogenetic background and virulence genotype of ciprofloxacin-susceptible and ciprofloxacin-resistant Escherichia coli strains of human and avian origin.
Graziani C; Luzzi I; Corro M; Tomei F; Parisi G; Giufre M; Morabito S; Caprioli A; Cerquetti M
J Infect Dis; 2009 Apr; 199(8):1209-17. PubMed ID: 19226230
[TBL] [Abstract][Full Text] [Related]
9. Composition of the outer membrane proteins of Escherichia coli strains in relation to serum susceptibility after exposure to subinhibitory concentrations of amikacin and ciprofloxacin.
Wojnicz D; Cisowska A
Int J Antimicrob Agents; 2009 Jun; 33(6):579-82. PubMed ID: 19232480
[TBL] [Abstract][Full Text] [Related]
10. The virulence factors and antibiotic sensitivities of Escherichia coli isolated from recurrent urinary tract infections.
Gulsun S; Oguzoglu N; Inan A; Ceran N
Saudi Med J; 2005 Nov; 26(11):1755-8. PubMed ID: 16311661
[TBL] [Abstract][Full Text] [Related]
11. Tamm-Horsfall protein inhibits binding of S- and P-fimbriated Escherichia coli to human renal tubular epithelial cells.
Leeker A; Kreft B; Sandmann J; Bates J; Wasenauer G; Múller H; Sack K; Kumar S
Exp Nephrol; 1997; 5(1):38-46. PubMed ID: 9052847
[TBL] [Abstract][Full Text] [Related]
12. Influence of berberine sulfate on synthesis and expression of Pap fimbrial adhesin in uropathogenic Escherichia coli.
Sun D; Abraham SN; Beachey EH
Antimicrob Agents Chemother; 1988 Aug; 32(8):1274-7. PubMed ID: 2903716
[TBL] [Abstract][Full Text] [Related]
13. Effect of subminimal inhibitory concentrations of pefloxacin on the piliation and adherence of E. coli.
Desnottes JF; Le Roy D; Diallo N
Drugs Exp Clin Res; 1988; 14(10):629-34. PubMed ID: 2907737
[TBL] [Abstract][Full Text] [Related]
14. Modulation of Escherichia coli type 1 fimbrial expression and adherence to uroepithelial cells following exposure of logarithmic phase cells to quinolones at subinhibitory concentrations.
Breines DM; Burnham JC
J Antimicrob Chemother; 1994 Aug; 34(2):205-21. PubMed ID: 7814281
[TBL] [Abstract][Full Text] [Related]
15. Clofibric and ethacrynic acids prevent experimental pyelonephritis by Escherichia coli in mice.
Balagué CE; de Ruiz CS; Rey R; de Duffard AM; Nader-Macías ME
FEMS Immunol Med Microbiol; 2004 Nov; 42(3):313-9. PubMed ID: 15477045
[TBL] [Abstract][Full Text] [Related]
16. Analysis of the variability of S-fimbriae expression in an Escherichia coli pathogen.
Ott M; Hacker J
FEMS Microbiol Lett; 1991 Apr; 63(2-3):233-8. PubMed ID: 1676382
[TBL] [Abstract][Full Text] [Related]
17. Molecular epidemiology of multi-resistant Escherichia coli.
Guyot A; Barrett SP; Threlfall EJ; Hampton MD; Cheasty T
J Hosp Infect; 1999 Sep; 43(1):39-48. PubMed ID: 10462638
[TBL] [Abstract][Full Text] [Related]
18. In vitro activity of prulifloxacin against Escherichia coli isolated from urinary tract infections and the biological cost of prulifloxacin resistance.
Gualco L; Schito AM; Schito GC; Marchese A
Int J Antimicrob Agents; 2007 Jun; 29(6):679-87. PubMed ID: 17363225
[TBL] [Abstract][Full Text] [Related]
19. Diagnostic value of a P-fimbriation test in determining duration of therapy in children with urinary tract infections.
Tambic T; Oberiter V; Delmis J; Tambic A
Clin Ther; 1992; 14(5):667-71. PubMed ID: 1361423
[TBL] [Abstract][Full Text] [Related]
20. Asparaginase inhibition of adhesion of type 1-fimbriated and P-fimbriated Escherichia coli to epithelial cell receptors.
Wehner MR; Koch SR; Kindinger L; Nelson N; Cowan MM
Appl Microbiol Biotechnol; 2004 Nov; 66(1):71-3. PubMed ID: 15455180
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
